affanpervez
Minister (2k+ posts)
Sanofi’s Dengue Vaccine Decreases Risk of Infection by 90 Percent
The dengue virus is transmitted by the mosquitoes Aedes aegypti and Aedes albopictus to humans. The infection usually manifests itself 4 to 7 days after the mosquito bite. The disease is common on tropical countries because of the high rainfall which is optimal for the mosquitoes' breeding. According to the World Health Organization, about 40 percent of the global population lives in dengue-risk areas. Up to 100 million people are infected, and 22,000 die yearly.
Sanofi successfully created the first vaccine for dengue fever and an extensive clinical study proved that it can provide moderate protection from the disease. (Photo : Reuters)
Sanofi successfully created the first vaccine for dengue fever and an extensive clinical study proved that it can provide moderate protection from the disease. Results of the trial concluded that the vaccine may be effective as an immune booster but not as efficient for people who had previous exposure, or currently infected with the virus. Therefore, it could be marketed as a vaccine for travelers visiting dengue-prone areas.The study involved 10, 275 children aged 2-14 from five countries in Asia. The company chose Asia as 75 percent of the dengue cases were from this continent while children have the highest fatality rate.
Sanofi allotted at least 1.3 billion and two decades for the vaccine's development. It also built a factory at Lyon in Southern France that is capable of producing at least 100 million doses of the vaccine per year.
Sanofi plans to create a special division to oversee the product's introduction to the market once it is accepted by all approving bodies.
http://www.hngn.com/articles/35955/20140712/sanofi-s-dengue-vaccine-decreases-risk-by-90-percent.htm
The dengue virus is transmitted by the mosquitoes Aedes aegypti and Aedes albopictus to humans. The infection usually manifests itself 4 to 7 days after the mosquito bite. The disease is common on tropical countries because of the high rainfall which is optimal for the mosquitoes' breeding. According to the World Health Organization, about 40 percent of the global population lives in dengue-risk areas. Up to 100 million people are infected, and 22,000 die yearly.
Sanofi successfully created the first vaccine for dengue fever and an extensive clinical study proved that it can provide moderate protection from the disease. (Photo : Reuters)
Sanofi successfully created the first vaccine for dengue fever and an extensive clinical study proved that it can provide moderate protection from the disease. Results of the trial concluded that the vaccine may be effective as an immune booster but not as efficient for people who had previous exposure, or currently infected with the virus. Therefore, it could be marketed as a vaccine for travelers visiting dengue-prone areas.The study involved 10, 275 children aged 2-14 from five countries in Asia. The company chose Asia as 75 percent of the dengue cases were from this continent while children have the highest fatality rate.
Sanofi allotted at least 1.3 billion and two decades for the vaccine's development. It also built a factory at Lyon in Southern France that is capable of producing at least 100 million doses of the vaccine per year.
Sanofi plans to create a special division to oversee the product's introduction to the market once it is accepted by all approving bodies.
http://www.hngn.com/articles/35955/20140712/sanofi-s-dengue-vaccine-decreases-risk-by-90-percent.htm
Last edited by a moderator:
